PMN
ProMIS Neurosciences Inc.Company Information
- Company Name
- ProMIS Neurosciences Inc.
- CIK
- CIK0001374339
- Category
- <br>Emerging growth company
- Ticker: Exchange
- PMN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- PMN
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-05
- Last sale
- 2025-06-30
- Shares purchased (TTM)
- 743,042
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 6,402,460
- Shares outstanding
- 9,142,366
- Ownership
- 70.03%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -14.81%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series2 Preferred Shares | - | - | - | - | - | - | 1 | - | - | - | 1 | - | ||||||
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 53 | 64 | 6 | 15 | 5 | 8 | 13 | 22 | 1 | 2 | 13 | 17 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 57 | 66 | 9 | 21 | 10 | 14 | 19 | 25 | 1 | 4 | 14 | 18 | ||||||
| Short Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 3 | 2 | 3 | 6 | 5 | 5 | 6 | 3 | 0 | 1 | 1 | 1 | ||||||
| Prepaid Expense Noncurrent | - | 2 | - | - | - | - | - | - | - | - | - | - | ||||||
| Assets | 57 | 67 | 9 | 21 | 10 | 14 | 19 | 25 | 1 | 4 | 14 | 18 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Accounts Payable Current | 2 | 2 | 3 | 4 | 3 | 1 | 2 | 2 | 2 | 1 | 8 | 8 | ||||||
Liabilities Current | ||||||||||||||||||
| Accrued Liabilities Current | 5 | 5 | 8 | 8 | 7 | 3 | 0 | 1 | 1 | 1 | 2 | 1 | ||||||
| Liabilities Current | 7 | 7 | 10 | 12 | 10 | 4 | 2 | 3 | 3 | 3 | 9 | 10 | ||||||
| Deferred Compensation Share Based Arrangements Liability Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent | 0 | 0 | - | 0 | 0 | 0 | - | 0 | 0 | 1 | - | 1 | ||||||
| Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares | - | - | - | 0 | 0 | 0 | 0 | 14 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 7 | 7 | 10 | 12 | 10 | 4 | 2 | 17 | 4 | 3 | 10 | 11 | ||||||
| Additional Paid In Capital | 200 | 200 | 130 | 129 | 108 | 108 | 108 | 98 | 98 | 98 | 98 | 97 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 49 | 61 | -1 | 9 | -0 | 9 | 16 | 7 | -2 | 0 | 4 | 7 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -150 | -139 | -130 | -120 | -108 | -98 | -91 | -90 | -100 | -97 | -93 | -90 | ||||||
| Liabilities And Stockholders Equity | 57 | 67 | 9 | 21 | 10 | 14 | 19 | 25 | 1 | 4 | 14 | 18 | ||||||
| Series1 Preferred Shares | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | - | - | - | - | - | - | 70 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | 0 | 1 | 1 | - | 70 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | 0 | 1 | 1 | - | 70 | ||||||
| Common Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Shares Issued | 9 | 9 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 9 | 9 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialProMIS Neurosciences Inc. (PMN) — SEC Financial Statements & Analysis
ProMIS Neurosciences Inc. (PMN) is a pharmaceutical preparations company, incorporated in Z4. ProMIS Neurosciences Inc. trades on Nasdaq as: PMN. ProMIS Neurosciences Inc. (PMN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, ProMIS Neurosciences Inc. carries a market cap of $120.31M, a P/E ratio of -2.85x, a P/B ratio of 2.44x, an enterprise value of $66.88M, and an EV/EBITDA multiple of -1.54x. On profitability, it posts a Return on Equity (ROE) of -172.30% and a Return on Assets (ROA) of -127.57%. Per share, it reports EPS of $-4.62, diluted EPS of $-4.62, free cash flow per share of $-4.61, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 401.09% year-over-year and EPS growth of -23.59% year-over-year. On the balance sheet, it maintains a current ratio of 7.85x, a quick ratio of 7.41x, working capital of $49.48M, a debt-to-equity ratio of 0.15x, a debt ratio of 0.13, an interest coverage ratio of -365.77x, free cash flow of $-42.11M (TTM), and net debt of $-53.43M. Figures sourced from SEC EDGAR.
- Market Cap
- $120.31M
- P/E TTM
- -2.85x
- EPS TTM
- $-4.62
- P/B TTM
- 2.44x
- ROE TTM
- -172.30%
- ROA TTM
- -127.57%
- Debt To Equity
- 0.15x
- Free Cash Flow TTM
- $-42.11M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ProMIS Neurosciences Inc. in?
ProMIS Neurosciences Inc. (PMN) operates in the Pharmaceutical Preparations industry.
What exchange does PMN trade on?
ProMIS Neurosciences Inc. (PMN) trades on the Nasdaq.
Where is ProMIS Neurosciences Inc. incorporated?
ProMIS Neurosciences Inc. is incorporated in Canada (Federal Level).
When was ProMIS Neurosciences Inc. (PMN)'s most recent SEC filing?
ProMIS Neurosciences Inc. (PMN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is PMN's market cap?
ProMIS Neurosciences Inc. (PMN) has a market capitalization of $120.31M as of 2026-06-30.
What is PMN's EPS (earnings per share)?
ProMIS Neurosciences Inc. (PMN)'s trailing twelve month EPS is $-4.62 as of 2026-06-30.
What is PMN's ROE (return on equity)?
ProMIS Neurosciences Inc. (PMN)'s trailing twelve month Return on Equity (ROE) is -172.30% as of 2026-06-30.
What is PMN's ROA (return on assets)?
ProMIS Neurosciences Inc. (PMN)'s trailing twelve month Return on Assets (ROA) is -127.57% as of 2026-06-30.
What is PMN's EV/EBITDA?
ProMIS Neurosciences Inc. (PMN)'s trailing twelve month EV/EBITDA is -1.54x as of 2026-06-30.